Abstract 2208P
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.
Methods
Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).
Results
Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.
Conclusions
Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07